下段直肠癌新辅助放化疗排除坐骨直肠窝照射可减少会阴并发症
该回顾性研究纳入2009年1月至2015年1月接受新辅助放化疗后腹会阴联合切除术的220例局部晚期下段直肠癌患者,比较坐骨直肠窝照射(IRF组90例)与未照射(NIRF组124例)的结局。IRF组会阴伤口并发症发生率为40.0%,NIRF组为24.2%(p=0.010);两组3年会阴复发率、无局部复发生存、总生存和无远处复发生存分别为4.4% vs 2.4%(p=0.670)、88.1% vs 95.0%(p=0.079)、82.6% vs 88.4%(p=0.087)和61.9% vs 81.0%(p=0.026)。多因素分析显示IRF照射与会阴伤口并发症显著相关(OR 2.892,p=0.002)。结论认为排除IRF照射可降低会阴伤口并发症而不影响肿瘤学结局。
要点
- IRF照射组会阴伤口并发症40.0%,未照射组24.2%(p=0.010)。
- IRF照射是会阴伤口并发症的独立危险因素(OR 2.892,p=0.002)。
- 排除IRF照射未显著损害肿瘤学结局,但需注意回顾性设计。
核心结论
- 局部晚期下段直肠癌新辅助调强放化疗中排除坐骨直肠窝照射可降低腹会阴联合切除术后会阴伤口并发症发生率,且不损害肿瘤学结局。
研究设计与样本
- 回顾性分析2009年1月至2015年1月接受新辅助放化疗后腹会阴联合切除术的220例局部晚期下段直肠癌患者,排除6例失访,IRF照射组90例,未照射组124例,比较生存、复发模式和治疗毒性。
主要发现
- IRF组和NIRF组会阴伤口并发症分别为40.0%和24.2%(p=0.010)。
- 两组3年会阴复发率分别为4.4%和2.4%(p=0.670),无局部复发生存分别为88.1%和95.0%(p=0.079),总生存分别为82.6%和88.4%(p=0.087),无远处复发生存分别为61.9%和81.0%(p=0.026)。
- 多因素分析显示IRF照射(OR 2.892,p=0.002)、贫血(OR 3.776,p=0.010)、手术时间>180分钟(OR 2.486,p=0.007)和放疗至手术间隔>8周(OR 2.400,p=0.010)与会阴伤口并发症显著相关。
临床怎么用
- 在局部晚期下段直肠癌新辅助调强放化疗制定临床靶区时,可考虑排除坐骨直肠窝以降低会阴伤口并发症,但需结合个体复发风险权衡。
局限性
- 本研究为单中心回顾性分析,两组手术技术存在不均衡,结果需前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The aim of this study was to explore the impact of including or excluding the ischiorectal fossa (IRF) within the clinical target volume during neoadjuvant chemoradiotherapy (NCRT) using intensity modulated radiotherapy, in locally advanced lower rectal cancer (LALRC). METHODS: We retrospectively analysed the data of 220 LALRC patients who received NCRT followed by abdominoperineal resection between January 2009 and January 2015. Six patients were excluded because of loss to follow-up, 90 patients received IRF irradiation (IRF group) while 124 patients did not (NIRF group). Survival, patterns of recurrence, and treatment toxicities were compared between the two groups. RESULTS: Overall, patient/treatment variables were well balanced except for surgical technique. Perineal wound complications in the IRF and NIRF groups, were 40.0 and 24.2%, respectively (p = 0.010); corresponding 3-year perineal recurrence rates, local recurrence free survival, overall survival, and distant relapse free survival were 4.4% vs. 2.4% (p = 0.670), 88.1% vs. 95.0% (p = 0.079), 82.6% vs. 88.4% (p = 0.087), and 61.9% vs. 81.0% (p = 0.026), respectively. Multivariate analyses demonstrated the following factors to be significantly related to perineal wound complications: irradiation of the IRF (odds ratio [OR] 2.892, p = 0.002), anaemia (OR 3.776, p = 0.010), operation duration > 180 min (OR 2.486, p = 0.007), and interval between radiotherapy and surgery > 8 weeks (OR 2.400, p = 0.010). CONCLUSIONS: Exclusion of the IRF from the clinical target volume during NCRT using intensity-modulated radiotherapy in LALRC could lower the incidence of perineal wound complications after abdominoperineal resection, without compromising oncological outcomes.
引用
- Song M, Geng J, Wang L, et al. Excluding the ischiorectal fossa irradiation during neoadjuvant chemoradiotherapy with intensity-modulated radiotherapy followed by abdominoperineal resection decreases perineal complications in patients with lower rectal cancer. Radiat Oncol. 2019. PMID: 31382984. doi:10.1186/s13014-019-1338-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。